Table 3 Characteristics of patients and monitoring of viral load in those receiving preemptive or therapeutic antiviral treatment
No patient | Type of transplant | Therapy | Weeks of follow-up at beginning therapy (duration in weeks) | Signs and symptoms | Viral load (copies/mL) before therapy | Viral load (copies/mL) after therapy |
|---|---|---|---|---|---|---|
1 | Liver | Valganciclovir | 14 (4) | asymptomatic | CMV viremia: 103 | No viremia |
8 | Liver | Valganciclovir | 11 (4) | asymptomatic | CMV viremia: 104 | No viremia |
22 | Liver | Valganciclovir | 10 (10) | Elevated AST, ALT | Viremia: CMV 104, EBV 10 | No viremia |
23 | Liver | Ganciclovir + Valganciclovir | 5 (5 days + 4) | Elevated AST, ALT | Viremia: CMV 104 | No viremia |
Urine: CMV 103 | Urine: no virus detected | |||||
12 | Kidney | Valganciclovir | 29 (4) | asymptomatic | Viremia: CMV 10, BKV 10 | No viremia |
Urine: CMV 102, BKV 107 | Urine: CMV 10, BKV 104 | |||||
15 | Kidney | Valganciclovir | 22 (4) | Fever | Viremia: CMV 102 | No viremia |
Urine: CMV 105 | Urine: no virus detected | |||||
34 (12) | Fever and chronic reject | Viremia: CMV 102 | No viremia | |||
Urine: CMV 106 | Urine: CMV 105 | |||||
18 | Kidney | Valganciclovir | 13 (12) | Urinary infection | Viremia: CMV 102 | No viremia |
Urine: CMV 103, BKV 102 | Urine: CMV 102 |